<DOC>
	<DOC>NCT02536703</DOC>
	<brief_summary>To confirm the safety and efficacy of the Lotusâ„¢ Valve System in the Chinese population for Transcatheter Aortic Valve Implantation (TAVI) in symptomatic patients with severe aortic stenosis.</brief_summary>
	<brief_title>Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population</brief_title>
	<detailed_description />
	<mesh_term>Constriction, Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1. Patients with symptomatic severe aortic stenosis (echocardiographic criteria: AV effective orifice area (EOA) of &lt; 1 cm2, mean AV gradient of &gt; 40 mmHg, or AV peak systolic velocity of &gt; 4.0 m/s; NYHAclass II or greater, angina pectoris, or syncope) 2. Subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent. 3. The subject agrees to comply with specified followup evaluations and to return to the investigational site where the procedure was performed. 4. Patients are technical and anatomical eligible for interventions 1. A known hypersensitivity or contraindication to any of the following which cannot be adequately premedicated: Aspirin Heparin (HIT/HITTS) and bivalirudin Nitinol (titanium or nickel) Ticlopidine and clopidogrel Contrast media 2. Subject refuses a blood transfusion. 3. Other medical, social, or psychological conditions that in the opinion of an Investigator precludes the subject from appropriate consent. 4. Native aortic annulus size &lt; 20 mm or &gt; 29 mm per the baseline diagnostic imaging. 5. Life expectancy is less than one year</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>